Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best penny stocks to buy for 2026. On January 6, the company confirmed ...

Australian shares were flat with a positive bias on Wednesday, amid softer-than-expected US inflation data. The S&P/ASX 200 was little changed to close at 8,820.6. Core US Consumer Price Index rose 0.

In 2018, Neuren partnered with ACADIA Pharmaceuticals, securing an upfront payment of US$100 million. ACADIA handles ...

Acadia Pharmaceuticals, partner of Neuren Pharmaceuticals, anticipates global net sales of its Rett syndrome treatment, ...

Neuren Pharmaceuticals (ASX: NEU) today shared highlights from partner Acadia Pharmaceuticals' presentation at the J.P.

Biotech company Neuren Pharmaceuticals has said projected global sales of its Rett syndrome treatment Daybue are set to reach ...

SYDNEY--Neuren Pharmaceuticals shares gained after its U.S. partner signaled global net sales of the Daybue treatment for Rett Syndrome could reach US$700 million in 2028. Shares were recently up 8.3% ...

Coleen Rooney returned to reality on Tuesday as she went on a big food shop at her local Waitrose . The I'm A Celebrity star, ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on ...

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across ...

Taysha Gene Therapies (TSHA) announced progress across the TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy with disease ...